Challenges of Using Circulating Tumour DNA: Insights from Advanced Prostate Cancer.
Where this comes from
- Record sourced from PubMed, PMID 42744693.
- Also identified by DOI 10.1016/j.eururo.2026.07.025.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Precision oncology relies on integrating tumour fraction, variant allele frequency, clonal haematopoiesis of indeterminate potential assessment, pathogenicity, and clinical context into next-generation sequencing interpretation, enabling biologically informed and clinically meaningful treatment decisions while reducing the risk of overinterpreting nontumour or nonactionable genomic alterations.